This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
HAYES, Inc.. Nivolumab (Opdivo) for treatment of non-small cell lung cancer. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016
Description of Technology: Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to programmed death (PD-1) pathway that is active in non-small cell lung cancer (NSCLC). Nivolumab inhibits PD-1, preventing it from interacting with its ligands and permitting activated T cells to attack tumor cells. Patient Population: Nivolumab is indicated for the treatment of metastatic NSCLC in patients with progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations should have disease progression on Food and Drug Administration (FDA)-approved therapy for these aberrations prior to receiving nivolumab.
Subject indexing assigned by CRD
Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: firstname.lastname@example.org
Date abstract record published